drugset / Trial / NCT00255463

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

NCT00255463

Phase 2 Completed 185 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the changes in a proliferation biomarker in subjects receiving Anastrozole or Anastrozole/ZD1839 combination.

Timeline

Start
2004-01
Primary completion
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified
Subject Gefitinib Small molecule

Indications